 NEXGEL NASDAQ:NXGL has announced positive results from its proof-of-concept study on idiclofenac hydrogel patches designed to treat pain caused by arthritis, joint pain, muscle aches and more. The Langhorne, Pennsylvania-based company said the study compared its diclofenac hydrogel patches with the leading commercially available topical treatment, assessing the formulations, skin retention and permeation of the products through the skin. 